Targeting the Renin–angiotensin–aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review
Current Treatment Options in Oncology · 2024-11 · 25 (11) · 1406-1427
DOI: 10.1007/s11864-024-01270-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 18.10.2024. Verfasst von J Pawlonka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland. jan.…. Hauptthemen laut MEDLINE: Renin-Angiotensin System, Neoplasms, Cardiovascular Diseases. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Opinion statement The renin–angiotensin–aldosterone system (RAAS) is a crucial regulator of the cardiovascular system and a target for widely used therapeutic drugs. Dysregulation of RAAS, implicated in prevalent diseases like hypertension and heart failure, has recently gained attention in oncological contexts due to its role in tumor biology and cardiovascular toxicities (CVTs). Thus, RAAS inhibitors (RAASi) may be used as potential supplementary therapies in cancer treatment and CVT prevention. Oncological treatments have evolved significantly, impacting patient survival and safety profiles. However, they pose cardiovascular risks, necessitating strategies for mitigating adverse effects. The main drug classes used in oncology include anthracyclines, anti-HER2 therapies, immune checkpoint inhibitors (ICIs), and vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSPI). While effective against cancer, these drugs induce varying CVTs. RAASi adjunctive therapy shows promise in enhancing clinical outcomes and protecting the cardiovascular system. Understanding RAAS involvement in cancer and CVT can inform personalized treatment approaches and improve patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland. jan.pawlonka@wum.edu.pl.
- Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland.
Zitieren
APA
Pawlonka, J., Buchalska, B., Buczma, K., Borzuta, H., Kamińska, K., & Cudnoch-Jędrzejewska, A. (2024). Targeting the Renin–angiotensin–aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review. Current Treatment Options in Oncology, 25(11), 1406-1427. https://doi.org/10.1007/s11864-024-01270-9
Vancouver
Pawlonka J, Buchalska B, Buczma K, Borzuta H, Kamińska K, Cudnoch-Jędrzejewska A. Targeting the Renin–angiotensin–aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review. Current Treatment Options in Oncology. 2024;25(11):1406-1427. doi:10.1007/s11864-024-01270-9
BibTeX
@article{Pawlonka2024,
author = {Pawlonka, J and Buchalska, B and Buczma, K and Borzuta, H and Kamińska, K and Cudnoch-Jędrzejewska, A},
title = {Targeting the Renin–angiotensin–aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review},
journal = {Current Treatment Options in Oncology},
year = {2024},
volume = {25},
number = {11},
pages = {1406--1427},
doi = {10.1007/s11864-024-01270-9}
}
EUVIMED